Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, topping the consensus estimate of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 39.74% and a negative net margin of 1,199.26%. The company […]
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) posted its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had […]
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) announced its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.45) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.64) by $0.19, Briefing.com reports. The firm had revenue of $8.19 million for the quarter, compared to analyst estimates of $8.37 million. Agios Pharmaceuticals […]
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) issued its quarterly earnings data on Thursday. The biopharmaceutical company reported ($1.45) EPS for the quarter, topping analysts’ consensus estimates of ($1.64) by $0.19, Briefing.com reports. Agios Pharmaceuticals had a negative return on equity of 38.08% and a negative net margin of 1,312.64%. The company had revenue of […]
Agios Pharmaceuticals (NASDAQ:AGIO – Get Free Report) had its price target hoisted by equities researchers at The Goldman Sachs Group from $29.00 to $33.00 in a report released on Friday, Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. The Goldman Sachs Group’s price target indicates a potential downside of […]